CD274 and non-small cell lung carcinoma: Recent advances have established immune checkpoint inhibitors (ICIs), including PD-1/PD-L1 inhibitors as standard-of-care treatment options for locally advanced and metastatic NSCLC patients [2,3,4,5,6,7,8,9].